Hybridoma-SFM
Hybridoma-SFM
Actual product may vary
Hybridoma-SFM
Hybridoma-SFM
Gibco™

Hybridoma-SFM

Gibco™ Hybridoma SFM은 항체 생성에서 hybridomas 성장을 돕기 위해 특별히 개발된 단백질 함량이 매우 낮은 무혈청 배지입니다. Gibco™ Hybridoma SFM의자세히 알아보기
Have Questions?
보기 방식 변경buttonViewtableView
카탈로그 번호수량
120450761000 mL
12045084500 mL
카탈로그 번호 12045076
제품 가격(KRW)
167,000
Each
카트에 추가하기
수량:
1000 mL
Customize this product
제품 가격(KRW)
167,000
Each
카트에 추가하기
Gibco™ Hybridoma SFM은 항체 생성에서 hybridomas 성장을 돕기 위해 특별히 개발된 단백질 함량이 매우 낮은 무혈청 배지입니다. Gibco™ Hybridoma SFM의 특징:
• 부유 및 고정 hybridomas, myelomas 지원
• 바로 사용할 수 있는 완전한 formulation
• 단백질 함량이 매우 낮은 무혈청 formulation

부유 및 고정 hybridomas, myelomas 지원
재조합 myeloma line 및 전통적인 hybridomas 배양에 적합한 Gibco™ Hybridoma SFM은 높은 세포 농도와 IgG 생산력을 제공합니다. NS0 등 콜레스테롤 의존성 배양에는 250x 콜레스테롤 지질 농축물을 첨가해야 합니다.

바로 사용할 수 있는 완전한 formulation
Gibco™ Hybridoma SFM은 바로 사용이 가능한 완전한 배지입니다. 보충이 필요하지 않습니다.

단백질 함량이 매우 낮은 무혈청 formulation
Gibco™ Hybridoma SFM은 단백질 함량이 매우 낮은 무혈청 formulation으로 관심 단백질 정제가 보다 쉽습니다. Gibco™ Hybridoma SFM에는 총 단백질 < 20 μg/ml가 들어있습니다.

용도
연구용 또는 제조용. 진단 절차에 사용할 수 없습니다. 제조 공정에 Gibco™ Hybridoma SFM을 사용하는 고객은 FDA 신청 시 라이프 테크놀로지스에 Type II Drug Master File (DMF) 참조 인증서를 요청할 수 있습니다.

cGMP 제조 품질 시스템
Gibco™ CD Hybridoma Medium은 뉴욕 Grand Island에 위치한 cGMP 준수 시설에서 제조됩니다. 이 시설은 의료기기 제조자로 FDA에 등록되어 있으며 ISO 13485, ISO 9001 인증을 받은 기관입니다.
For Research Use Only. Not for use in diagnostic procedures.
사양
세포 유형Hybridomas
제품라인Gibco
제품 유형Serum Free Medium (SFM)
수량1000 mL
배송 조건Room Temperature
분류Low Protein, Serum-free
형태Liquid
Serum LevelSerum-free
첨가제 포함Glutamine, Phenol Red
Unit SizeEach
구성 및 보관
Storage conditions: 2-8°C. Protect from light
Shipping conditions: Ambient
Shelf life: 12 months from date of manufacture

자주 묻는 질문(FAQ)

How do I adapt my cells to serum-free medium?

Cells can be adapted by Sequential or Direct Adaptation. Suggested protocols for each are below, and you can also find more information by searching "Adaptation of Cell Cultures to a Serum-Free Medium" from our website home page.

SEQUENTIAL ADAPTATION
1) Subculture the cells growing in serum-supplemented medium into a 25%:75% mixture of SFM and serum supplemented medium.
2) When the cell density is 5 x 10E5 cells/ml, subculture the cells into a 50%:50% mixture of SFM and serum supplemented medium at a cell density 2.5 x 10E5 to 3 x 10E5 cells/ml.
3) Continue to subculture after the cell density 5 x 10E5 cells/ml in gradually increasing proportions of SFM until the serum is ~0.1% with about 85% cell viability.
4) Subculture the cells into SFM with an innoculum of 2.5 x 10E5 to 3 x 10E5 cells/ml.
5) When the cell density is 1 x 10E6 to 3 x 10E6 cells/ml (4 to 6 days post planting) subculture the cells again.
6) Stock cultures of SFM adapted cells should be subcultured in SFM every 3 to 5 days when the cell density is 1 x 10E6 to 3 x 10E6 cells/ml with 90% viability.

DIRECT ADAPTATION
Some cells can be directly adapted from serum-containing medium to SFM. For direct adaptation, the cell innoculum should be 1.5 x 10E5 to 3 x 10E5 cells/ml.
Cells should be subcultured when the cell density is 1 x 10E6 to 3 x 10E6 cells/ml. Cells are fully adapted to SFM when the cell density is 2 x 10E6 to 4 x 10E6 cells/ml after 4 to 7 days in culture.
Stock cultures of cells adapted to SFM should be subcultured in SFM every 3 to 5 days when the cell density is 1 x 10E6 to 3 x 10E6 cells/ml with 90% viability.

Why is it necessary to gradually adapt the cells to serum-free medium?

Some cells, such as insect cells, are sensitive to changes in their medium. By sequentially adapting cells, the medium is changed with minimal effects on cell growth.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

인용 및 참조 문헌 (3)

인용 및 참조 문헌
Abstract
High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells.
Authors: Durocher Yves; Perret Sylvie; Kamen Amine;
Journal:Nucleic Acids Res
PubMed ID:11788735
A scalable transfection procedure using polyethylenimine (PEI) is described for the human embryonic kidney 293 cell line grown in suspension. Green fluorescent protein (GFP) and human placental secreted alkaline phosphatase (SEAP) were used as reporter genes to monitor transfection efficiency and productivity. Up to 75% of GFP-positive cells were obtained ... More
Properties and pharmacokinetics of two humanized antibodies specific for L-selectin.
Authors: Co M S; Landolfi N F; Nagy J O; Tan J H; Vexler V; Vasquez M; Roark L; Yuan S; Hinton P R; Melrose J; Klingbeil C; Queen C; Berg E L;
Journal:Immunotechnology
PubMed ID:10231094
BACKGROUND: The participation of L-selectin in leukocyte recruitment during inflammation has suggested the use of L-selectin inhibitors as potential anti-inflammatory therapeutics. Blocking monoclonal antibodies could serve as such therapeutic agents, particularly if humanized to reduce their immunogenicity and improve their serum half-life. OBJECTIVES: For this purpose, two mouse monoclonal antibodies, ... More
Serum-free production of recombinant proteins and adenoviral vectors by 293SF-3F6 cells.
Authors:Cote J; Garnier A; Massie B; Kamen A;
Journal:Biotechnol Bioeng
PubMed ID:10099373
This article describes the step-wise approach undertaken to select a serum-free medium (SFM) for the efficient production of a recombinant adenoviral vectors expressing beta-galactosidase (Ad5 CMV-LacZ), in the complementing human embryonic kidney 293S cells. In the first step, a 293S-derived transfectoma, secreting a soluble epidermal growth factor receptor sEGFr (D2-22), ... More